Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook as of early 2026. Despite a 2.37% gain on 4 Aug 2026, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum measures. This analysis delves into the evolving technical landscape of this small-cap pharmaceutical player, contextualising its recent price action and longer-term trends against sector and benchmark indices.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 02 August 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO. This rating was last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 11 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating moving averages and momentum oscillators, suggests increasing downside pressure amid a challenging market environment for the Pharmaceuticals & Biotechnology sector.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 June 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Astrazeneca Pharma India Ltd has experienced a nuanced shift in its technical momentum, with recent data revealing a transition from a sideways trend to a mildly bearish stance. Despite a modest day gain of 0.61%, the stock’s technical indicators present a complex picture, reflecting both bullish and bearish signals across weekly and monthly timeframes.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

AstraZeneca Pharma India Ltd. reported a challenging quarter for Q4 FY26 (January-March 2026), with net profit declining to ₹44.88 crores, down 22.96% quarter-on-quarter (QoQ) from ₹58.25 crores in Q3 FY26, despite posting robust revenue growth of 20.42% year-on-year (YoY). The stock reacted sharply to the mixed results, declining 5.17% to close at ₹8,520.00 on May 27, 2026, as investors grappled with deteriorating margins and profitability concerns despite the company's strong topline momentum.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a 2.19% gain on 20 May 2026, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This nuanced technical landscape warrants a detailed analysis for investors seeking clarity on the stock’s near-term trajectory.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 May 2026, providing investors with an up-to-date view of its performance and outlook.

Astrazeneca Pharma India Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical indicators suggest a cautiously evolving outlook for this small-cap pharmaceutical player.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO. This rating was last updated on 02 Jan 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 06 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a bearish to a mildly bearish trend as of early 2026. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s mixed technical signals across key indicators such as MACD, RSI, Bollinger Bands, and moving averages suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Despite some bullish signals on longer-term indicators, the overall technical landscape suggests caution for investors as the stock contends with downward pressure amid mixed momentum indicators and a recent downgrade in its Mojo Grade to Sell.